Loading...

MIRA MIRA PHARMACEUTICALS INC Investments/Divestments 8-K Filing

MR P

MR

MIRA PHARMACEUTICALS INC

(MIRA)

2024 8-K

Show Summary

Show Summary

Asset Acquisitions

Clinical Trials

Product Expansion

Positive Study Results

Clinical Trial Launch

Acquisition Agreement

Product Development

Clinical Trial Approval

Accounting Firm Change

Drug Safety Validation

Management Changes

Clinical Trial Announcement

Ketamir-2 Efficacy

Ketamine Study Results

Annual Meeting Results

Drug Development Update

Preclinical Success

Compliance Regained

Preclinical Study Data on K...

Preclinical Success

Delisting Notice

Changes in Management

Board Restructuring and Res...

Discovery of New Molecule

Resignation of Director

Appointment and Resignation

License Agreement and Loan ...

Appointment and Resignation...

Amendment to Employment Agr...

Public Offering

External Links:

Mira Pharmaceuticals discloses new insights from preclinical study data on Ketamir-2, a selective inhibitor of the NMDA receptor, with potential benefits of reduced side effects, improved safety profile, and enhanced therapeutic effectiveness.

AI Assistant

MIRA PHARMACEUTICALS INC

2024

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.